LIU to host annual specialty pharmacy symposium
BROOKLYN, N.Y. A university’s pharmacy program is hosting its annual symposium on specialty pharmacy.
Long Island University’s 30th Annual Arnold Schwartz Memorial Program, which will be held June 13 at the LaGuardia Marriott in East Elmhurst, N.Y., is designed to give pharmacists and other healthcare providers the tools to engage the specialty drug market. The symposium will include several guest speakers and discuss such topics as:
- Definition of Specialty Pharmacy Practice-overview, statistics about growth and direction
- Disease states that are being treated with specialty drugs, i.e., MS, growth deficiencies, RA, hemophilia
- Economics and billing of specialty pharmaceuticals
- How to enter the specialty market
- Operating a specialty pharmacy
There will be registration and continental breakfast beginning at 7:30 a.m. with the program beginning at 8 a.m. A luncheon will be served approximately at noon and the program will conclude at 3 p.m.
The program is sponsored by a grant from Cardinal Health.
Study finds Victoza more effective in treating Type 2 diabetes than competitor
PRINCETON, N.J. A study published online in the journal Diabetes Care indicated that a once-daily diabetes drug made by Novo Nordisk “further improves” blood sugar control and weight loss when patients switch to it from a competitor made by Eli Lilly, Novo Nordisk announced Tuesday.
The study, conducted by the Danish drug maker, was a 26-week study in Type 2 diabetes patients taking Novo Nordisk’s Victoza (liraglutide) or Lilly’s twice-daily Byetta (exenatide). The drugs are the only glucagon-like peptide-1, or GLP-1 agonists available on the market.
“Clinical benefits were seen in patients who switched from exenatide to Victoza,” University of North Carolina School of Medicine Diabetes Care Center director and study investigator John Buse said. “The significant improvements in blood sugar lowering and fasting glucose confirm the original findings of the trial regarding the efficacy of Victoza.”
Hospira completes Orchid acquisition
LAKE FOREST, Ill. Hospira has completed its $400 million acquisition of the generic injectables business of Orchid Chemicals & Pharmaceuticals, the generic drug maker announced Tuesday.
“We are excited to acquire new capabilities that will create opportunities for commercial growth, position us strongly in a key antibiotics product area, expand our global footprint and enhance our ability to provide lower-cost, high-quality products to patients,” Hospira COO Terry Kearney said. “We’re also excited to welcome a talented base of 450 employees, including newly appointed managing director [for] Hospira India, Dr. C.B. Rao, who joins us with a wealth of diversified industrial and management experience, and will provide continuity of leadership for the Orchid team joining Hospira.”
The acquisition, announced in February, includes Orchid’s beta-lactam antibiotic formuatlions manufacturing complex — comprising penicillin, cephalosporin and carbapenem facilities — and a pharmaceutical research and development facility in Irungattukottai, Chennai.